Drugs / AXA1125
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05152849 | Dec 2021 → Jun 2022 | long COVID-19 | Axcella Health, Inc | Completed | Missed primary |
| Phase 2 | NCT04880187 | May 2021 → Sep 2023 | metabolic dysfunction-associated steatohepatitis | Axcella Health, Inc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXA1125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05152849 ↗ |
| Modality | Other / unclassified | “an endogenous metabolic modulator (AXA1125)” PMID 37223439 ↗ Apr 2023 |
| Route | Oral | “22.6 g AXA1125 administered orally BID with or without food” NCT04880187 ↗ |